BridgeBio Pharma, Inc.BBIONASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -33.22% | +237.08% | -44.76% | +4999.86% | +4318.01% |
| Gross Profit Growth | -38.91% | +231.12% | -45.85% | +6709.68% | +5248.50% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | -30529.15% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +15.43% | +8.58% | +6.40% | +1.56% | +1.06% |
| Weighted Average Shares Diluted Growth | +15.43% | +8.58% | +6.40% | +1.56% | +1.06% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -208.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -218.71% | +0.00% |
| Receivables Growth | -90.75% | +169.67% | -51.05% | +11546.67% | +24276.15% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +1.52% | +68.26% | +3.80% | +35.98% | +50.12% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -0.30% | -0.53% | +7.49% | +54.81% | +7.51% |
| R&D Expense Growth | -3.75% | +0.10% | -20.96% | -3.02% | -6.29% |
| SG&A Expenses Growth | +92.36% | +99.19% | +61.63% | +116.98% | +99.98% |